Skip to content

Efficacy of epinastine hydrochloride ophthalmic solution in the patients with perennial allergic conjunctivitis after treating with olopatadine hydrochloride ophthalmic solution.

Efficacy of epinastine hydrochloride ophthalmic solution in the patients with perennial allergic conjunctivitis after treating with olopatadine hydrochloride ophthalmic solution. - Efficacy of epinastine hydrochloride ophthalmic solution in the patients with perennial allergic conjunctivitis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016025
Enrollment
50
Registered
2014-12-25
Start date
2014-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial allergic conjunctivitis

Interventions

Sponsors

Oka ophthalmology clinic, incorporated medical institution
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients aged 16 years or older 2)Patients diagnosed as perennial allergic conjunctivitis in the both eyes. 3)Patients with moderate or severe ocular pruritus and switching medication after treated with olopatadine hydrochloride ophthalmic solution for two weeks or more at the time of informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients given immunotherapy (hyposensitization therapy, modulated therapy) . 2)Patients with ocular pruritus and hyperemia caused by a disease other than allergic conjunctivitis which will influence drug evaluation. 3)Patients with a history of atopic keratoconjunctivitis, spring catarrh, giant papillary conjunctivitis, corneal herpes, recurrent corneal erosion caused by the frequent occurrence of corneal injury or dry eye. 4)Patients with surgical history in the internal eye (including laser therapy) within 90 days prior to initiation of the clinical research. 5)Patients with possibility taking medicines (including anti-allergic agent, immunosuppressive drugs and adrenal cortex steroid except eye drops) which affect the efficacy of study drug. However, the use of ophthalmic solutions of adrenal cortex steroid is admitted as needed if there is no improvement in symptoms. 6)Females who are or may be pregnant, or lactating 7)Patients with a history of hypersensitivity to study drug 8)Patients with severe complications (such as immediate hospitalized care is required) which are identified inappropriate for safety reason. 9)Patients who have any other reasons that causes the study doctor to deem a subject unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Improvement rate of pruritus and hyperemia Change in scores of subjective symptoms, change in scores of objective findings, change of value in patient diary and questionnaire items

Countries

Japan

Contacts

Public ContactYoshitaka Oka

Oka ophthalmology clinic, incorporated medical institution Oka ophthalmology clinic, incorporated medical institution

mail@okaganka.com0948-22-5155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026